SGX-listed iX Biopharma has launched a programme to develop a sublingual dexmedetomidine wafer for the treatment of agitation in dementia and other indications.The programme is part of the company’s strategy to repurpose existing approved drugs using its proprietary WaferiX drug delivery platform ...

Specialty pharmaceutical company iX Biopharma has reported revenue of $14.4 million for the FY2022 ended June, an eight-fold, or 725% increase from its FY2021 revenue of $1.7 million.The revenue surge was mainly driven by the upfront payment received from the group’s Wafermine out-licensing deal w...

THE following companies saw new developments that may affect trading of their securities on Tuesday (Aug 23): Singapore Telecommunications (Singtel): Bloomberg sources cited in an article on Monday said the telecommunications company is going forward with a planned sale of its cyber security...

PHARMACEUTICAL company iX Biopharma posted an S$8.3 million loss for the second half of the fiscal year ended June 2022, sinking deeper into the red from a S$5.4 million loss in H2 FY2021.

iX Biopharma plans to raise $2.7 million by placing out 13.7 million new shares at 20 cents each to C2C Biopharma, described as the investment vehicle of one Lundy Nath.According to iX Biopharma, Nath has more than 20 years of corporate experience in the US and Cambodia, in the health and wellness i...

CATALIST-LISTED iX Biopharma has swung back into the black with a net profit of S$3.7 million for the first half of its fiscal year ended Dec 31, 2021, compared with a net loss of S$2.8 million the previous year.

iX Biopharma has reported net profit of $3.7 million for the 1HFY2022 ended December, reversing from its loss of $2.8 million in the same period the year before. 1HFY2022 earnings per share (EPS) stood at 0.49 cents from the loss per share of 0.41 cents in the 1HFY2020. Revenue surged nearly 16 ti...

iX Biopharma, a Singapore-listed specialty pharmaceutical company with expertise in drug delivery systems, has worked consistently on developing a wide range of medications, closing deals and partnerships, and improving investments in medical technology to capture a share of the multibillion-dollar ...

In its 2022 outlook strategy report dated Jan 6, PhillipCapital’s head of research Paul Chew has listed four themes he expects to see during the year. These are: inflation peaking and the easing of supply chain constraints; vaccines to bend mortality [rates]; modestly higher interest rates and a r...

PhillipCapital analyst Paul Chew maintains “buy” rating on iX Biopharma with an increased target price to 35.5 cents from 33.5 cents, as the analyst incorporates a higher upfront fee of $12.1 million and raised expected development income. iX Biopharma has signed an outlicensing agreement for it...

CATALIST-LISED iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics - a clinical-stage biopharmaceutical company.

Pharmaceuticals company iX Biopharma has signed an exclusive license agreement with Seelos Therapeutics for its product, Wafermine. Under terms of the agreement, iX Biopharma will receive an upfront payment of US$9 million ($12 million) to be satisfied in cash and shares. iX Biopharma is also elig...

CATALIST-LISED iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics - a clinical-stage biopharmaceutical company.

PHARMACEUTICAL company iX Biopharma, through its wholly-owned subsidiary, has struck an agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) for the licensing, supply and distribution of Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunctio...

iX Biopharma has entered into an agreement with China Resources Pharmaceutical Commercial Group on Sept 30, for the licensing, supply and distribution of Wafesil in China. Wafesil is a sublingual sildenafil wafer that treats male erectile dysfunction. The agreement was signed with the group’s wh...